# Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease

> **NCT05007678** · PHASE3 · COMPLETED · sponsor: **Ashford and St. Peter's Hospitals NHS Trust** · enrollment: 178 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** leflunomide

## Key facts

- **NCT ID:** NCT05007678
- **Lead sponsor:** Ashford and St. Peter's Hospitals NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-16
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05007678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05007678, "Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05007678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*